Active substance
Triazolam
- US FDA 8
- Health Canada 1
- US price lines 2
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| HALCION | 0.25MG; 0.125MG | tablet · oral | PFIZER | Prescription | 15 Nov 1982 |
| TRIAZOLAM | 0.125MG; 0.25MG | tablet · oral | INGENUS PHARMS LLC | Prescription | 20 Oct 2020 |
| TRIAZOLAM | 0.125MG; 0.25MG | tablet · oral | ZYDUS PHARMS | Prescription | 28 Dec 2022 |
| HALCION | 0.5MG | tablet · oral | PFIZER | Discontinued | 15 Nov 1982 |
| TRIAZOLAM | 0.125MG; 0.25MG | tablet · oral | PHARMOBEDIENT | Discontinued | 25 Mar 1994 |
| TRIAZOLAM | 0.125MG; 0.25MG | tablet · oral | HIKMA PHARMS | Discontinued | 1 Jun 1994 |
| TRIAZOLAM | 0.125MG; 0.25MG | tablet · oral | WATSON LABS | Discontinued | 20 Oct 1995 |
| TRIAZOLAM | 0.125MG; 0.25MG | tablet · oral | BRECKENRIDGE | Discontinued | 8 Nov 2022 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| TRIAZOLAM | 00808571 | 0.25 MG | TABLET · ORAL | AA PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | TRIAZOLAM 0.125 MG TABLET | $0.26282 | per EA | 23 Sep 2026 |
| US NADAC | TRIAZOLAM 0.25 MG TABLET | $0.30835 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 27 Oct 2021 HALCION — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.